TIMOTHY P. NOYES - 29 Jan 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
AVTE
Transactions as of
29 Jan 2024
Transactions value $
$0
Form type
4
Filing time
31 Jan 2024, 18:00:06 UTC
Previous filing
03 Nov 2023
Next filing
03 Apr 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +200,000 $0.000000 200,000 29 Jan 2024 Common Stock 200,000 $18.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 29, 2024.